SSGJ-705

Phase 2Small molecule

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

SSGJ-705 is one of 74 small molecule programs targeting Metastatic Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Solid TumorsRecruiting

Advanced Malignant TumorsRecruiting

Combination TherapyRecruiting

Metastatic Solid TumorsPhase 2

Recruiting

Advanced Malignant TumorsPhase 1

Recruiting

Combination TherapyPhase 2

Recruiting

Competition

Competitive Landscape

56 competitors in Combination Therapy

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

1 2

Ritalin

Novartis

Phase 3

1 3

Avastin

Roche

Phase 2

5 4

Liposomal Doxorubicin

Eli Lilly

Phase 3

1 5

Keytruda

Merck & Co.

Phase 2

3 6

Taxol

Teva

Phase 2

3 7

Beyfortus

BeiGene

Phase 2

3 8

Gleevec

Novartis

Phase 2

2 9

Braftovi

Pfizer

Phase 2

1 10

Cabometyx

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Advanced Malignant Tumors

NCT06390774

Q4 2027

Phase 2Recruiting

Combination Therapy

NCT07022002

Q4 2028

Phase 2Recruiting

Metastatic Solid Tumors

NCT07646626

Clinical

Trials by Indication[1]

Advanced Malignant Tumors1 trial

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 1·NCT06390774·180 enrolled

Solid Tumors1 trial

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Unknown status·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 1·NCT05145179·162 enrolled

Combination Therapy1 trial

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 2·NCT07022002·340 enrolled

Metastatic Solid Tumors1 trial

A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 2·NCT07646626·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SSGJ-705. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SSGJ-705 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SSGJ-705. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

SSGJ-705

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Advanced Malignant Tumors1 trial

Solid Tumors1 trial

Combination Therapy1 trial

Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News